tbuckley/cabot-search huggingface dataset:
Estimating the effect of transitioning to a strength-based alcohol tax system on alcohol consumption and health outcomes: a modelling study of tax reform in England
Authors: Damon Morris, Colin Angus, Duncan Gillespie, Abigail K Stevely, Robert Pryce, Luke Wilson, Madeleine Henney, Petra S Meier, John Holmes, Alan Brennan
Journal: The Lancet Public Health (2024)

Increasing the amount of alcohol taxation is among the most effective measures for addressing the rising global burden of alcohol harm. However, less is known about the effect of changing alcohol tax structures. Substantial reforms to UK alcohol taxation structures enacted in August, 2023, mean that all alcohol is taxed based on its ethanol content, beers and ciders sold in on-trade premises (eg, public houses) are taxed at a reduced rate (hereafter called draught relief), and beer and particularly cider remain taxed at lower rates than other alcohol of equivalent strength. We aimed to model the effect of these reforms on alcohol consumption and health and economic outcomes, and the effects of hypothetical alternative scenarios.
Generative artificial intelligence and ethical considerations in health care: a scoping review and ethics checklist
Authors: Yilin Ning, Salinelat Teixayavong, Yuqing Shang, Julian Savulescu, Vaishaanth Nagaraj, Di Miao, Mayli Mertens, Daniel Shu Wei Ting, Jasmine Chiat Ling Ong, Mingxuan Liu, Jiuwen Cao, Michael Dunn, Roger Vaughan, Marcus Eng Hock Ong, Joseph Jao-Yiu Sung, Eric J Topol, Nan Liu
Journal: The Lancet Digital Health (2024)
Single-cell AI-based detection and prognostic and predictive value of DNA mismatch repair deficiency in colorectal cancer
Authors: Marta Nowak, Faiz Jabbar, Ann-Katrin Rodewald, Luciana Gneo, Tijana Tomasevic, Andrea Harkin, Tim Iveson, Mark Saunders, Rachel Kerr, Karin Oein, Noori Maka, Jennifer Hay, Joanne Edwards, Ian Tomlinson, Owen Sansom, Caroline Kelly, Francesco Pezzella, David Kerr, Alistair Easton, Enric Domingo, Viktor H Koelzer, David N Church
Journal: Cell Reports Medicine (2024)
Clinical symptoms and psychosocial functioning in patients with schizophrenia spectrum disorders testing seropositive for anti-NMDAR antibodies: a case–control comparison with patients testing negative
Authors: Jurjen J Luykx, Robbert Visscher, Inge Winter-van Rossum, Patrick Waters, Lot D de Witte, W Wolfgang Fleischhacker, Bochao Danae Lin, Nini de Boer, Marte van der Horst, Ksenija Yeeles, Michael Davidson, Thomas A Pollak, Alkomiet Hasan, Belinda R Lennox
Journal: The Lancet Psychiatry (2024)
Glycan-specific IgM is critical for human immunity to Staphylococcus aureus
Authors: Astrid Hendriks, Priscilla F Kerkman, Meri R J Varkila, Jelle L G Haitsma Mulier, Sara Ali, Thijs Ten Doesschate, Thomas W van der Vaart, Carla J C de Haas, Piet C Aerts, Olaf L Cremer, Marc J M Bonten, Victor Nizet, George Y Liu, Jeroen D C Codée, Suzan H M Rooijakkers, Jos A G van Strijp, Nina M van Sorge
Journal: Cell Reports Medicine (2024)
mLumiOpto is a Mitochondrial-Targeted Gene Therapy for Treating Cancer
Authors: Kai Chen, Patrick Ernst, Anusua Sarkar, Seulhee Kim, Yingnan Si, Tanvi Varadkar, Matthew D. Ringel, Xiaoguang Liu, Lufang Zhou
Journal: Cancer Research (2024)

Abstract Mitochondria are important in various aspects of cancer development and progression. Targeting mitochondria in cancer cells holds great therapeutic promise, yet current strategies to specifically and effectively destroy cancer mitochondria in vivo are limited. Here, we developed mLumiOpto, an innovative mitochondrial-targeted luminoptogenetics gene therapy designed to directly disrupt the inner mitochondrial membrane (IMM) potential and induce cancer cell death. The therapeutic approach included synthesis of a blue light-gated cationic channelrhodopsin (CoChR) in the IMM and co-expression of a blue bioluminescence-emitting nanoluciferase (NLuc) in the cytosol of the same cells. The mLumiOpto genes were selectively delivered to cancer cells in vivo by an adeno-associated virus (AAV) carrying a cancer-specific promoter or cancer-targeted monoclonal antibody-tagged exosome-associated AAV (mAb-Exo-AAV). Induction with NLuc luciferin elicited robust endogenous bioluminescence, which activated CoChR, triggering cancer cell mitochondrial depolarization and subsequent cell death. Importantly, mLumiOpto demonstrated remarkable efficacy in reducing tumor burden and killing tumor cells in glioblastoma and triple-negative breast cancer xenograft mouse models. Furthermore, the approach induced an anti-tumor immune response, increasing infiltration of dendritic cells and CD8+ T cells in the tumor microenvironment. These findings establish mLumiOpto as a promising therapeutic strategy by targeting cancer cell mitochondria in vivo.
The 77th World Health Assembly resolution calling for newborn screening, diagnosis, and management of birth defects: moving towards action in low-income and middle-income countries
Authors: Pui-Ying Iroh Tam, Carmencita D Padilla, Stanley Zlotkin, Adejumoke Idowu Ayede, Tahmina Banu, Janet Kayita, Rajesh Khanna, Suman Pn Rao, Khalid Siddeeg, Salimah Walani, Ayesha de Costa
Journal: The Lancet Global Health (2024)
Carvedilol to Improve Cardiac Remodeling in Anthracycline-Exposed Childhood Cancer Survivors
Authors: Saro H Armenian, Melissa M Hudson, Lanie Lindenfeld, Sitong Chen, Eric J Chow, Steven Colan, Meagan Echevarria, F Lennie Wong, Ming Hui Chen, Smita Bhatia
Journal: JACC CardioOncology (2024)
Childhood-onset systemic lupus erythematosus in China, 2016–21: a nationwide study
Authors: Sihao Gao, Zhongxun Yu, Xudong Ma, Jialu Sun, Aiguo Ren, Sifa Gao, Mengchun Gong, Xiang Zhou, Mingsheng Ma, Hongmei Song
Journal: The Lancet Child & Adolescent Health (2024)
Conduct disorder: the need for research on Asian populations
Authors: Riza Amalia, Arbin Janu Setiyowati, Ronal Surya Aditya, Eva Meizara Puspita Dewi, Syafrida Selfiardy, Rizky Andana Pohan, Dewi Ariani, Fatimah Setiani
Journal: The Lancet Psychiatry (2024)
Adverse outcomes and mortality in individuals with eating disorder-related electrolyte abnormalities in Ontario, Canada: a population-based cohort study
Authors: Marco Solmi, Nicholas Fabiano, Anna E Clarke, Stephen G Fung, Peter Tanuseputro, Greg Knoll, Daniel T Myran, Ann Bugeja, Manish M Sood, Gregory L Hundemer
Journal: The Lancet Psychiatry (2024)
Microbiota regulates neonatal disease tolerance to virus-evoked necrotizing enterocolitis by shaping the STAT1-NLRC5 axis in the intestinal epithelium
Authors: Saravanan Subramanian, Hua Geng, Longtao Wu, Chao Du, Amy M Peiper, Heng-Fu Bu, Pauline M Chou, Xiao Wang, Stephanie C Tan, Neha R Iyer, Nazeer Hussain Khan, Ellen L Zechner, James G Fox, Rolf Breinbauer, Chao Qi, Bakhtiar Yamini, Jenny P Ting, Isabelle G De Plaen, Stephanie M Karst, Xiao-Di Tan
Journal: Cell Host & Microbe (2024)
Comprehensive analyses of a large human gut Bacteroidales culture collection reveal species- and strain-level diversity and evolution
Authors: Zhenrun J Zhang, Cody G Cole, Michael J Coyne, Huaiying Lin, Nicholas Dylla, Rita C Smith, Téa E Pappas, Shannon A Townson, Nina Laliwala, Emily Waligurski, Ramanujam Ramaswamy, Che Woodson, Victoria Burgo, Jessica C Little, David Moran, Amber Rose, Mary McMillin, Emma McSpadden, Anitha Sundararajan, Ashley M Sidebottom, Eric G Pamer, Laurie E Comstock
Journal: Cell Host & Microbe (2024)
Definitions of adverse events associated with extracorporeal membrane oxygenation in children: results of an international Delphi process from the ECMO-CENTRAL ARC
Authors: Peta M A Alexander, Matteo Di Nardo, Alain Combes, Adam M Vogel, Marta Velia Antonini, Nicholas Barrett, Giulia M Benedetti, Amanda Bettencourt, Daniel Brodie, René Gómez-Gutiérrez, Stephen M Gorga, Carol Hodgson, Poonam Malhotra Kapoor, Jennifer Le, Graeme MacLaren, Erika R O'Neil, Marlies Ostermann, Matthew L Paden, Neil Patel, Alvaro Rojas-Peña, Ahmed S Said, Francesca Sperotto, Ariane Willems, Leen Vercaemst, Ajit P Yoganathan, Angela Lorts, Pedro J Del Nido, Ryan P Barbaro
Journal: The Lancet Child & Adolescent Health (2024)
Networks of human milk microbiota are associated with host genomics, childhood asthma, and allergic sensitization
Authors: Zhi Yi Fang, Sara A Stickley, Amirthagowri Ambalavanan, Yang Zhang, Amanda M Zacharias, Kelsey Fehr, Shirin Moossavi, Charisse Petersen, Kozeta Miliku, Piushkumar J Mandhane, Elinor Simons, Theo J Moraes, Malcolm R Sears, Michael G Surette, Padmaja Subbarao, Stuart E Turvey, Meghan B Azad, Qingling Duan
Journal: Cell Host & Microbe (2024)
Salmonella Typhimurium screen identifies shifts in mixed-acid fermentation during gut colonization
Authors: Bidong D Nguyen, Anna Sintsova, Christopher Schubert, Andreas Sichert, Clio Scheidegger, Jana Näf, Julien Huttman, Verena Lentsch, Tim Keys, Christoph Rutschmann, Philipp Christen, Patrick Kiefer, Philipp Keller, Manja Barthel, Miguelangel Cuenca, Beat Christen, Uwe Sauer, Emma Slack, Julia A Vorholt, Shinichi Sunagawa, Wolf-Dietrich Hardt
Journal: Cell Host & Microbe (2024)
AI-Driven Innovations in Alzheimer's Disease: Integrating Early Diagnosis, Personalized Treatment, and Prognostic Modelling
Authors: Mayur B Kale, Nitu L Wankhede, Rupali S Pawar, Suhas Ballal, Rohit Kumawat, Manish Goswami, Mohammad Khalid, Brijesh G Taksande, Aman B Upaganlawar, Milind J Umekar, Spandana Rajendra Kopalli, Sushruta Koppula
Journal: Ageing Research Reviews (2024)
PDIA3 defines a novel subset of adipose macrophages to exacerbate the development of obesity and metabolic disorders
Authors: Jia-Hui Luo, Fa-Xi Wang, Jia-Wei Zhao, Chun-Liang Yang, Shan-Jie Rong, Wan-Ying Lu, Qi-Jie Chen, Qing Zhou, Jun Xiao, Ya-Nan Wang, Xi Luo, Yang Li, Dan-Ni Song, Cai Chen, Cheng-Liang Zhang, Su-Hua Chen, Ping Yang, Fei Xiong, Qi-Lin Yu, Shu Zhang, Shi-Wei Liu, Fei Sun, Cong-Yi Wang
Journal: Cell Metabolism (2024)
Preclinical lentiviral vector-mediated hematopoietic stem and progenitor cell gene therapy corrects Pompe disease-related muscle and neurological manifestations
Authors: John K Yoon, Jeffrey W Schindler, Mariana Loperfido, Cristina Baricordi, Mark P DeAndrade, Mary E Jacobs, Christopher Treleaven, Robert N Plasschaert, Aimin Yan, Cecilia N Barese, Yildirim Dogan, Vicky Ping Chen, Claudia Fiorini, Fritz Hull, Luigi Barbarossa, Zeenath Unnisa, Daniel Ivanov, Robert H Kutner, Swaroopa Guda, Christine Oborski, Tim Maiwald, Véronique Michaud, Michael Rothe, Axel Schambach, Richard Pfeifer, Chris Mason, Luca Biasco, Niek P van Til
Journal: Molecular Therapy (2024)
Hypermethylation and downregulation of microRNA219a-2 activates the ALDH1L2/GSH/PAI-1 pathway for fibronectin degradation in renal fibrosis
Authors: Qingqing Wei, Xiao Xiao, Emily Huo, Chunyuan Guo, Xiangjun Zhou, Xiaoru Hu, Charles Dong, Huidong Shi, Zheng Dong
Journal: Molecular Therapy (2024)
SafeRPlan: Safe deep reinforcement learning for intraoperative planning of pedicle screw placement
Authors: Yunke Ao, Hooman Esfandiari, Fabio Carrillo, Christoph J Laux, Yarden As, Ruixuan Li, Kaat Van Assche, Ayoob Davoodi, Nicola A Cavalcanti, Mazda Farshad, Benjamin F Grewe, Emmanuel Vander Poorten, Andreas Krause, Philipp Fürnstahl
Journal: Medical Image Analysis (2024)

Spinal fusion surgery requires highly accurate implantation of pedicle screw implants, which must be conducted in critical proximity to vital structures with a limited view of the anatomy. Robotic surgery systems have been proposed to improve placement accuracy. Despite remarkable advances, current robotic systems still lack advanced mechanisms for continuous updating of surgical plans during procedures, which hinders attaining higher levels of robotic autonomy. These systems adhere to conventional rigid registration concepts, relying on the alignment of preoperative planning to the intraoperative anatomy. In this paper, we propose a safe deep reinforcement learning (DRL) planning approach (SafeRPlan) for robotic spine surgery that leverages intraoperative observation for continuous path planning of pedicle screw placement. The main contributions of our method are (1) the capability to ensure safe actions by introducing an uncertainty-aware distance-based safety filter; (2) the ability to compensate for incomplete intraoperative anatomical information, by encoding a-priori knowledge of anatomical structures with neural networks pre-trained on pre-operative images; and (3) the capability to generalize over unseen observation noise thanks to the novel domain randomization techniques. Planning quality was assessed by quantitative comparison with the baseline approaches, gold standard (GS) and qualitative evaluation by expert surgeons. In experiments with human model datasets, our approach was capable of achieving over 5% higher safety rates compared to baseline approaches, even under realistic observation noise. To the best of our knowledge, SafeRPlan is the first safety-aware DRL planning approach specifically designed for robotic spine surgery.
Semi-supervised ViT knowledge distillation network with style transfer normalization for colorectal liver metastases survival prediction
Authors: Mohamed El Amine Elforaici, Emmanuel Montagnon, Francisco Perdigón Romero, William Trung Le, Feryel Azzi, Dominique Trudel, Bich Nguyen, Simon Turcotte, An Tang, Samuel Kadoury
Journal: Medical Image Analysis (2024)
222P Artificial intelligence (AI) based prognostication from baseline computed tomography (CT) scans in a phase III advanced non-small cell lung cancer (aNSCLC) trial
Authors: O.F. Khan, J. Montalt-Tordera, J. Riskas, S.A. Haider, V. Sivan, O. Samorodova, J. Hennessy, A. Mitchell, S.S. Mohammadi, E. Di Tomaso, T. Banerji, F. Baldauf-Lenschen, C. Glaus
Journal: Annals of Oncology (2024)
LBA33 ICON9: International phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy
Authors: S. Nicum, J.A. Ledermann, L. Mileshkin, G.C. Jayson, C. Gourley, A. Michael, R. Lord, H. Mackay, M. Hall, L. Tookman, S. Banerjee, P. Harnett, I. Macdonald, Y.C. Lee, O. Elyashiv, K. Wilkinson, L. Farrelly, N. Counsell
Journal: Annals of Oncology (2024)
224P Lung cancer scRNA-seq analyses reveal potential mechanisms causing different efficacy of target therapy and immunotherapy between EGFR 19del and L858R lung adenocarcinoma
Authors: H. Wang, Y. Zhang, Y. Xu, W. Zhao, L. Zhao, K. Xu, L. Ye, X. Liu, Y. Liu, W. Zhang, Z. Chen, Y. Ma, J. Shuai, J. Su, Y. He
Journal: Annals of Oncology (2024)
223P Tumor whole genome sequencing-based ultrasensitive ctDNA analysis as an early biomarker for clinical outcome in immune checkpoint inhibitor (ICI) phase I clinical trials (Ph1) and a tool for beyond progressive disease by iRECIST
Authors: R.D.A. Toledo, A.M. Calahorro García, A.B. Moreno, O. Mirallas, V. Galvao, G. Alonso Casal, M. Vieito, I. Braña, A. Oberoi, M.J. Lostes Bardaji, K.C. Keough, F. Navarro, J. Jimenez, A. Mel Olano, P.G. Nuciforo, C. Abbott, J.L. Pugh, R. Chen, S. Boyle, E. Garralda
Journal: Annals of Oncology (2024)
LBA24 Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: 3-year disease-free survival from NICHE-2
Authors: M. Chalabi, L.D.W. van den Dungen, Y.L. Verschoor, S. Balduzzi, P.G.M. de Gooyer, N. Kok, E. Kerver, C. Grootscholten, E.E. Voest, J.W.A. Burger, E.R. Hendriks, T.R. de Wijkerslooth, T. Tin, T.S. Aukema, S.J. Oosterling, A.G. Aalbers, J.G. van den Berg, M.E. van Leerdam, T.N. Schumacher, J.B.A.G. Haanen
Journal: Annals of Oncology (2024)
LBA2 POD1UM-303/InterAACT 2: Phase III study of retifanlimab with carboplatin-paclitaxel (c-p) in patients (Pts) with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) not previously treated with systemic chemotherapy (Chemo)
Authors: S. Rao, E. Samalin-Scalzi, L. Evesque, M. Ben Abdelghani, F. Morano, A.C. Roy, L. Dahan, S. Tamberi, A.S. Dhadda, M.P. Saunders, N. Casanova, R. Guimbaud, A. Lievre, J. Maurel, M. Fakih, P. Zhang, J. Harrison, M. Jones, J-P. Spano, P. Rochefort
Journal: Annals of Oncology (2024)
LBA38 Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy in first-line (1L) treatment of advanced hepatocellular carcinoma (aHCC): A randomized, open-label, phase II/III study (DUBHE-H-308)
Authors: S. Qin, J. Fan, F. Yang, J. Zhou, Y. Zhang, D. Cai, Z. Yu, Y. Chen, X. Shi, D. Li, Y. Li, J. Yao, Y. Tan, D. Wu, X. Yang, M. Da, L. Li, P. Shao, X. Kang
Journal: Annals of Oncology (2024)
229TiP A phase II trial of a neural network-based treatment decision support tool in patients (pts) with refractory solid organ malignancies
Authors: R.J. Walsh, A. Jayagopal, T.Z. Tan, J. Pitt, R. Sundar, S.C. Lee, B-C. Goh, V. Rajan, D.S. Tan, A.D. Jeyasekharan
Journal: Annals of Oncology (2024)
LBA28 ENGOT-en11/GOG-3053/KEYNOTE-B21: A phase III study of pembrolizumab or placebo in combination with adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer
Authors: T. Van Gorp, L. Rob, W. Lu, F. Backes, F. Ortaç, K. Hasegawa, S.H. Hietanen, A. Savarese, A. Laenen, Y.M. Kim, L. Bodnar, M.P. Barretina Ginesta, L. Gilbert, B. Pothuri, X. Chen, J. Lichfield, W. Wang, R.J. Orlowski, A. Lortholary, B.M. Slomovitz
Journal: Annals of Oncology (2024)
LBA27 First-in-human results of STX-478, a mutant-selective PI3Ka inhibitor, in advanced solid tumor patients
Authors: A.J. Montero, A. Giordano, K. Jhaveri, P. Munster, J. Rodon, P. Lorusso, D. Orr, J. Bartolomé Arcilla, A. Italiano, A. Elias, A. Soyano, M. De Miguel, B. Doger de Spéville, G. Daniele, J. O'Shaughnessy, T.C. Hernandez Guerrero, R. Wesolowski, C. Saura Manich, M. Chao, D. Juric
Journal: Annals of Oncology (2024)
188P Integration of immunohistochemistry and transcriptomics reveals new insights into the immune landscape of soft-tissue sarcomas
Authors: G. Petroni, F. Scolari, E. Caliman, R. Scanferla, G. Scoccianti, B. Menicacci, A. Palomba, F. Nozzoli, D.A. Campanacci, L. Antonuzzo, S. Pillozzi
Journal: Annals of Oncology (2024)
LBA36 A randomised phase II study to evaluate the efficacy and safety of androgen deprivation therapy (ADT) vs chemotherapy (CT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancers
Authors: L.F.L. Licitra, L.D. Locati, L. Digue, C. Even, A. Psyrri, P.M. Clement, S. Ochsenreither, J-P. Delord, C. Moro, J-P. Machiels, T. Fuereder, A-S. Govaerts, P. Quattrone, L. De Cecco, F. Perrone, M. Rasschaert, A. Nzokirantevye, A. Joaquim, E. Venslovaite, C. Fortpied Lefevre
Journal: Annals of Oncology (2024)
LBA9 Clinical insights from ultra-sensitive tumour-informed ctDNA tracking across the TRACERx cohort
Authors: J.R.M. Black, T. Karasaki, C. Abbott, S. Boyle, B. Li, M. Al Bakir, W.K. Liu, S. Veeriah, M. Jamal-Hanjani, N. McGranahan, A.M. Frankell, R. Chen, C. Swanton
Journal: Annals of Oncology (2024)
LBA17 Survival outcome of neoadjuvant endocrine therapy + trastuzumab and pertuzumab (ET+T+P) vs. de-escalated chemotherapy (CT)+T+P in hormone receptor positive (HR+)/HER2+ early breast cancer (EBC): WSG-TP-II trial
Authors: O. Gluz, U.A. Nitz, M. Christgen, S. Kummel, J. Holtschmidt, J. Schumacher, A.D. Hartkopf, K. Luedtke-Heckenkamp, M. Just, R. von Schumann, S. Polata, T. Schinköthe, M.K. Graeser-Mayer, R.E. Kates, R. Würstlein, H. Kreipe, N. Harbeck
Journal: Annals of Oncology (2024)
LBA21 Human epidermal growth factor receptor 2 (HER2)-low and HER2-ultralow status determination in tumors of patients (pts) with hormone receptor–positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06)
Authors: R.F. Salgado, A. Bardia, G. Curigliano, X. Hu, R.A. Dent, J-Y. Pierga, J. Tsurutani, H. Wildiers, G.R.R. Ricciardi, C. Marchiò, F. Penault-Llorca, C. Bor-Angelier, A. Andrzejuk-Cwik, A. Darilay, T. Matsuo, R. Shami, F. Jones, G. Viale
Journal: Annals of Oncology (2024)
195P Preclinical efficacy of the trastuzumab duocarmazine SYD985 as monotherapy or in combination with the PARP inhibitor niraparib in HER2-expressing endometrial cancer
Authors: E. Colas, C.P. Moiola, C. Lopez Gil, M. Rebull, M. Denizli, A. Sotoca Covaleda, V. Bebia Conesa, L. Salazar, S. Cabrera, M. van der Vleuten, P. Groothuis, A. Gil-Moreno
Journal: Annals of Oncology (2024)
196P Randomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring DNA repair deficiencies
Authors: R.F. Schlenk, M. Rübsam, M-V. Teleanu, S. Richter, J.T. Siveke, S. Wagner, H-G. Kopp, T. Kindler, L. Illert, A.H-E. Golf, K. Dorman, N. Schreck, A. Benner, H. Süsse, A. Freitag, C. von Kalle, H. Glimm, D. Hübschmann, S. Fröhling, C.E. Heilig
Journal: Annals of Oncology (2024)
208P Role of plasma exosomes in crosstalk between immune system and hereditary ovarian cancer: Opportunity or challenge?
Authors: D. Fanale, L.R. Corsini, U. Randazzo, C. Brando, A. Perez, T.D. Bazan Russo, P. Ferraro, A. Simone, M. Bono, E. Pedone, P. Piraino, S. Contino, O. Prestifilippo, V. Gennusa, A. Galvano, L. Incorvaia, G. Badalamenti, J.L. Iovanna, A. Russo, V. Bazan
Journal: Annals of Oncology (2024)
LBA12 eMouvoir: Randomised phase III trial evaluating the impact of a personalized and remote physical activity (PA) for breast cancer survivors (BCS). Results on the quality of life (QoL)
Authors: L. Vanlemmens, C. Lefeuvre-Plesse, J. Thery, E. Bogart, E. Aymes, M-A. Brochard, F. Le Gall, M. Belmimoun, L. Rotsaert, H. Mocaer, J.B. Prevost, D. Chocteau, H. Rhliouch, G. Lauridant Philippin, T. Mulliez, A. Najem, A-C. Hardy-Bessard, E. Lartigau, A. Anota, M-C. Le Deley
Journal: Annals of Oncology (2024)
201P Efficacy of antibody drug conjugate (ADC) by mRNA expression of targeted genes in advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN-2
Authors: T. Fujisawa, Y. Nakamura, N. Sakamoto, T. Hashimoto, M. Nagamine, T. Kuwata, G. Ishii, R. Yamashita, C. Morizane, N. Nonomura, H. Iwata, S. Okano, H. Watari, K. Namikawa, T. Shibuki, M. Imai-Sumida, H. Bando, M. Radovich, G. Sledge, T. Yoshino
Journal: Annals of Oncology (2024)
LBA35 Primary results from TACTI-003: A randomized phase IIb trial comparing eftilagimod alpha (soluble LAG-3) plus pembrolizumab versus pembrolizumab alone in first-line recurrent or metastatic head and neck squamous cell carcinoma with CPS ≥1
Authors: C.A. Kristensen, R. Metcalf, I. Braña, S. Laban, A. Soria Rivas, D. Grose, J. Rubio Casadevall, V. Cheshuk, S.M. Dieter, A. Lopez Pousa, S. Kasper-Virchow, B. Doger de Spéville, M. Covela, F.D. Vogl, C. Mueller, F. Triebel
Journal: Annals of Oncology (2024)
1475TiP Fruquintinib in combination with sintilimab and CAPEOX as first-line treatment for advanced G/GEJ cancer: A phase Ib/II clinical trial (FUNCTION)
Authors: B-B. Chen, X. Chen, G. Chen, Y. Wu, G. Zhang, Z. Zhan, X. Han, F. Zhou, W. Bai, Y. Guo, M. Gao, C. Lu, X. Gao, Y. Chen, P. Shi, G. Zhang, Z. Min, X. Chen
Journal: Annals of Oncology (2024)
LBA50 Perioperative nivolumab (NIVO) v placebo (PBO) in patients (pts) with resectable NSCLC: Clinical update from the phase III CheckMate 77T study
Authors: M. Provencio Pulla, M. Awad, T. Cascone, J.D. Spicer, J. He, S. Lu, A. Alexandru, Y. Watanabe, R. Cornelissen, L.D.O. Koch, J. Kuzdzal, J-L. Pujol, P. Hoffknecht, J.E. Gray, C. Coronado Erdmann, J. Neely, V. Devas, S. Bhatia, F. Tanaka
Journal: Annals of Oncology (2024)
LBA51 Circulating tumor DNA (ctDNA) dynamics and treatment responses in chemotherapy-ineligible patients (pts) with unresectable stage III NSCLC from the phase II DUART trial
Authors: A.R. Filippi, M.R. Garcia-Campelo, J-B. Paoli, D.M. Kowalski, C. Bennati, P. Borghetti, D.L. Cortinovis, A. Delmonte, C. Genova, R.M. Mroz, S. Nawrocki, I. Toledano, G. Tonini, R. Stewart, Z. Zhu, G. Wetherill, N.E. Georgoulia, I. Diaz Perez, R. Dziadziuszko
Journal: Annals of Oncology (2024)
LBA39 Updated efficacy and safety data from IMbrave050: Phase III study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)
Authors: A. Yopp, M. Kudo, M. Chen, A-L. Cheng, A.O. Kaseb, H.C. Lee, S. Qin, E. Cha, S.P. Hack, Q. Lian, J. Spahn, C. Wu, P. Chow
Journal: Annals of Oncology (2024)